Mobidiag secures EUR 25 million from European Investment Bank
Investment Plan for Europe: Mobidiag secures EUR 25 million from EIB. Funds will be used to accelerate the development and commercialisation of in vitro diagnostic solutions for infectious diseases.
Since 2016, the EIB has contributed significantly to the growth of Mobidiag through the provision of a EUR 15 million loan facility, the final tranche of which was obtained in November 2018. The loan enabled Mobidiag to successfully achieve a number of operational milestones in the development, validation and subsequent launch of the innovative and proprietary ‘sample-in, result-out’ diagnostic solution Novodiag®. With this new EUR 25 million loan, Mobidiag will continue to seek growth through the extension of its product pipeline.
Advancing data technologies to corner AMR 2019
International Matchmaking Symposium on 5 June, 2019 in Amsterdam, The Netherlands.
Artificial Intelligence, Internet-of-Things and Blockchain to stop ever-escalating Antimicrobial resistance.